Bank Julius Baer & Co. Ltd Zurich grew its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 4.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 807,532 shares of the medical technology company’s stock after purchasing an additional 34,765 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Stryker were worth $284,145,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of SYK. Czech National Bank increased its holdings in shares of Stryker by 3.9% during the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after buying an additional 3,366 shares in the last quarter. Davis R M Inc. increased its holdings in shares of Stryker by 1.8% during the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after buying an additional 2,512 shares in the last quarter. Terra Alpha Investments LLC acquired a new position in shares of Stryker during the third quarter worth $1,216,000. Kepler Cheuvreux Suisse SA acquired a new position in shares of Stryker during the third quarter worth $27,952,000. Finally, Daymark Wealth Partners LLC increased its holdings in shares of Stryker by 436.0% during the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after buying an additional 37,307 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.
Stryker Price Performance
SYK stock opened at $302.14 on Thursday. The stock has a market capitalization of $115.83 billion, a PE ratio of 34.97, a price-to-earnings-growth ratio of 1.86 and a beta of 0.80. The company’s 50-day moving average is $332.77 and its 200-day moving average is $352.58. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87.
Stryker Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.
Insider Buying and Selling at Stryker
In related news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.60% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Jefferies Financial Group restated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Citigroup decreased their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. BTIG Research decreased their price objective on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Leerink Partners started coverage on shares of Stryker in a research report on Monday, April 13th. They set an “outperform” rating and a $410.00 price target on the stock. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.
Check Out Our Latest Report on SYK
Stryker Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
- Five stocks we like better than Stryker
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
